ParagonRx and Campbell Alliance, both inVentiv Health companies, are again teaming up to provide a solution to a growing need of pharmaceutical clients.
By integrating the broad REMS expertise of ParagonRx with the organizational development expertise of Campbell Alliance, we are providing services to help clients define the roles, governance, procedures, and metrics for optimal risk management operations.
In the four years since REMS was established by the FDA Amendments Act, many pharmaceutical companies have worked through the growing pains of creating their first REMS programs, establishing REMS compliance measures, and submitting periodic reports to FDA. Many leading companies are creating dedicated risk management roles to serve as a center of excellence for this new discipline, but the process of defining roles, creating SOPs, and documenting governance has proved to be challenging.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.